153 related articles for article (PubMed ID: 28627808)
1. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success.
Mahjoub R; Ødegaard F; Zaric GS
Health Econ; 2018 Jan; 27(1):e15-e25. PubMed ID: 28627808
[TBL] [Abstract][Full Text] [Related]
2. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
Zaric GS; Xie B
Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
[TBL] [Abstract][Full Text] [Related]
3. Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach.
Gavious A; Greenberg D; Hammerman A; Segev E
Eur J Health Econ; 2014 Jun; 15(5):553-61. PubMed ID: 24326947
[TBL] [Abstract][Full Text] [Related]
4. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
Badia X; Prior M
Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
[No Abstract] [Full Text] [Related]
5. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
[TBL] [Abstract][Full Text] [Related]
6. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Critchley GJ; Zaric GS
Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
[TBL] [Abstract][Full Text] [Related]
7. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
Goldhaber-Fiebert JD; Cipriano LE
Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
[TBL] [Abstract][Full Text] [Related]
8. The effects of rebate contracts on the health care system.
Graf J
Eur J Health Econ; 2014 Jun; 15(5):477-87. PubMed ID: 23793870
[TBL] [Abstract][Full Text] [Related]
9. Using price-volume agreements to manage pharmaceutical leakage and off-label promotion.
Zhang H; Zaric GS
Eur J Health Econ; 2015 Sep; 16(7):747-61. PubMed ID: 25193525
[TBL] [Abstract][Full Text] [Related]
10. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
Towse A; Garrison LP
Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
[TBL] [Abstract][Full Text] [Related]
11. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
Barros PP
Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
[TBL] [Abstract][Full Text] [Related]
12. The economics of licensing contracts.
Mason R; Savva N; Scholtes S
Nat Biotechnol; 2008 Aug; 26(8):855-7. PubMed ID: 18700253
[No Abstract] [Full Text] [Related]
13. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
14. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
[TBL] [Abstract][Full Text] [Related]
15. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies.
Morgan S; Daw J; Thomson P
Health Aff (Millwood); 2013 Apr; 32(4):771-7. PubMed ID: 23569058
[TBL] [Abstract][Full Text] [Related]
16. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
Zaric GS; O'brien BJ
Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
[TBL] [Abstract][Full Text] [Related]
17. Pricing schemes for new drugs: a welfare analysis.
Levaggi R
Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
[TBL] [Abstract][Full Text] [Related]
18. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
Zaric GS
Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
[TBL] [Abstract][Full Text] [Related]
19. Parallel imports under a manufacturer rebate and a price freeze: Evidence from Germany.
Birg L
Health Econ; 2023 Feb; 32(2):302-323. PubMed ID: 36336829
[TBL] [Abstract][Full Text] [Related]
20. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
Maskineh C; Nasser SC
Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
